Profile data is unavailable for this security.
About the company
ZIM Laboratories Limited is a pharmaceutical company. The Company develops, manufactures and supplies oral, solid differentiated generic pharmaceutical formulations and pre-formulation intermediaries (PFI) in various therapeutic segments. Its delivery solutions cover product conceptualization product development, filing for registration, manufacture, and supply of various pharmaceutical formulations. It is developing products in various therapeutic segments like, central nervous system, anti-biotic and anti-infective, gastrointestinal, cardiovascular, analgesic/pain management, urology and vitamins, minerals, and dietary supplements. Its technological capabilities include drug release modification, solubility and stability enhancement, taste masking and dosage form transformation. Its product offerings include finished formulations and pre-formulations intermediates, which include granules, pellets, taste-masked powders, dry suspensions, tablets, capsules, and oral thin films.
- Revenue in INR (TTM)3.67bn
- Net income in INR172.46m
- Incorporated1984
- Employees525.00
- LocationZIM Laboratories LtdSadoday Gyan (Ground Floor)Opp. NADT, Nelson Square,NAGPUR 440013IndiaIND
- Phone+91 7 122981960
- Fax+91 7 118271470
- Websitehttps://www.zimlab.in/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lyka Labs Ltd | 1.06bn | -35.60m | 4.07bn | 713.00 | -- | -- | 41.35 | 3.85 | -1.23 | -1.23 | 33.69 | -- | -- | -- | -- | -- | -- | -5.48 | -- | -9.31 | 61.37 | 59.75 | -3.34 | -10.63 | -- | 0.5422 | -- | -- | -52.05 | 8.95 | -133.88 | -- | 17.78 | -- |
| Venus Remedies Ltd. | 5.62bn | 290.26m | 4.13bn | 998.00 | 14.22 | -- | 7.14 | 0.7348 | 21.73 | 21.73 | 420.31 | -- | -- | -- | -- | 5,630,556.00 | -- | 2.84 | -- | 3.84 | 42.76 | 39.68 | 5.17 | 3.83 | -- | 559.36 | -- | -- | -7.21 | 8.33 | -34.77 | -- | -10.05 | -- |
| Wanbury Ltd | 5.69bn | 233.39m | 4.91bn | 1.58k | 21.07 | -- | 13.58 | 0.8629 | 7.12 | 7.12 | 173.80 | -- | -- | -- | -- | 3,598,099.00 | -- | 6.56 | -- | -- | 46.15 | 43.92 | 4.10 | 4.54 | -- | 1.82 | -- | -- | -2.26 | 5.95 | -112.76 | -- | 34.73 | -- |
| Kilitch Drugs (India) Ltd | 1.55bn | 145.71m | 5.52bn | 153.00 | 37.24 | -- | 34.21 | 3.56 | 9.21 | 9.21 | 98.24 | -- | -- | -- | -- | 10,132,730.00 | -- | 2.63 | -- | 3.59 | 39.68 | 33.85 | 8.25 | 5.01 | -- | 3.43 | -- | 2.93 | 22.20 | 22.30 | 41.82 | 15.19 | 1.79 | -- |
| ZIM Laboratories Ltd | 3.67bn | 172.46m | 5.53bn | 525.00 | 32.08 | 2.32 | 16.65 | 1.50 | 3.54 | 3.54 | 75.34 | 49.00 | 0.9321 | 2.54 | 3.76 | -- | 4.38 | 3.88 | 6.66 | 6.54 | 53.34 | 48.30 | 4.69 | 3.97 | 0.9182 | 3.67 | 0.3131 | -- | -7.80 | 1.84 | -29.42 | 2.37 | 29.41 | -- |
| Valiant Laboratories Ltd | -100.00bn | -100.00bn | 6.18bn | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 60.35 | -- | 27.66 | -- | -- | -- |
| IND Swift Laboratories Ltd | 12.81bn | 3.07bn | 6.60bn | 1.50k | 2.15 | 0.7089 | 1.83 | 0.5155 | 51.99 | 51.99 | 216.90 | 157.64 | 0.857 | 3.45 | 3.80 | -- | 20.58 | 5.00 | 25.67 | 6.13 | 39.47 | 42.82 | 24.02 | 8.52 | 2.94 | 1.70 | 0.0175 | -- | 6.10 | 11.10 | 784.44 | 70.82 | 23.60 | -- |
| Medicamen Biotech Ltd | 1.71bn | 126.93m | 6.63bn | 388.00 | 53.35 | -- | 36.53 | 3.89 | 9.78 | 9.78 | 131.89 | -- | -- | -- | -- | 4,398,250.00 | -- | 7.17 | -- | 10.44 | 46.88 | 33.85 | 6.58 | 10.87 | -- | 4.76 | -- | 8.61 | 22.02 | 4.77 | -0.3555 | 7.98 | -4.21 | 0.00 |
| Albert David Ltd | 3.62bn | 754.20m | 6.68bn | 1.27k | 8.86 | 1.74 | 8.12 | 1.84 | 132.16 | 132.16 | 635.16 | 671.05 | 0.7868 | 2.67 | 12.15 | -- | 16.37 | 10.00 | 20.85 | 13.15 | 65.30 | 61.03 | 20.81 | 11.87 | 3.31 | 124.70 | 0.0086 | 12.89 | 6.12 | 2.72 | 108.49 | 33.59 | 40.87 | 13.90 |
